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A B S T R A C T
Background: Foodborne Neglected Zoonotic Helminths (FNZH) are parasites of both economic and public health
importance. They include Taenia solium, Echinococcus granulosus sensu lato, Echinococcus multilocularis and
Foodborne trematodes (FBT). FNZH are earmarked for major interventions for control, elimination and eradi-
cation. This systematic review highlights the progress towards development of rapid tests for the diagnosis of
FNZH since 2010 when they were listed as neglected tropical diseases.
Methodology: A systematic search was conducted in three databases, World of Science, Embase and PubMed
using the same search phrase. The search produced 480 hits. Three studies from back referencing were included.
Only 22 of these met the inclusion criteria. Data was extracted from these and presented qualitatively.
Results: Twenty-five rapid diagnostic tests were found to have been developed since 2010, eight for diagnosis of
T. solium infections, eight for echinococcosis and nine for FBT infections. The rapid tests for diagnosing T. solium
infections included six antibody detecting and two antigen detecting tests. They constitute a combination among
them, with some tests providing qualitative, others quantitative results. Similarly, seven out of the eight rapid
tests developed for Echinococcus infections were antibody detecting tests save for one loop mediated isothermal
amplification test. All of them were qualitative tests. For FBT infections, nine rapid tests were described; two
antibody and one nucleic acid detecting test for diagnosis of Fascioliasis; three nucleic acid detecting tests for
Opisthorchiasis; one antibody detecting test for Paragonimiasis; and for Clonorchiasis, one antibody and one
nucleic acid detecting test. The FBT infection rapid tests were all qualitative in nature.
Most of these tests have not undergone field evaluation in endemic areas where they will be used most.
Conclusion: This review describes the development and evaluation of rapid diagnostic tests, while highlighting
the need for in depth validations of the tools to determine how well they can perform in endemic areas.
1. Introduction
Foodborne Neglected Zoonotic Helminths (FNZH) are a component
of the Neglected Zoonotic Diseases (NZD), a subgroup of Neglected
Tropical Diseases (NTDs) recognized by the World Health Organization
(“WHO | Neglected zoonotic diseases,” 2015). FNZH include Taenia
solium, Echinococcus granulosus sensu lato (s.l.), E. multilocularis and
Foodborne trematodes (FBT). T. solium, E. granulosus s.l. and E. multi-
locularis rank first, second and third, respectively, among the multi-
criteria based ranking of important foodborne parasites. The various
FBT collectively constitute a large score of important foodborne para-
sites in the same ranking (FAO/WHO, 2014). Collectively, the FNZH are
reportedly responsible for 649,433 illnesses, 44,033 deaths, 2,837,363
years of life lost, 2,336,038 years lived with disability and 5,183,418
disability adjusted life years globally (DALYs) (WHO, 2015a).
The WHO has developed strategies for prevention, control, elim-
ination and possibly eradication of FNZHs (WHO, 2015b). In order to
track progress, implementation targets and milestones have been set for
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each disease. To measure progress towards these milestones, mon-
itoring and evaluation and disease surveillance will be essential. As
such, there will be need for optimal diagnostic tools throughout the
implementation process in order to provide robust and credible evi-
dence on the performance of specific interventions (Savioli, 2012).
Besides, diagnostics are needed for individual patient care in resource
limited settings. Currently, diagnostic tests for FNZH in humans vary
from simple microscopy to advanced imaging and molecular techni-
ques.
T. solium taeniosis is diagnosed routinely by classical methods of
demonstrating parasite material, eggs, scolices or proglottids, in feces
using a microscope. However, microscopy has low sensitivity and
cannot differentiate the eggs of closely related Taenia spp. and poses
high risk of infection (Allan and Craig, 2006; Mwape and Gabriël,
2014). Improved techniques such as copro-antigen enzyme-linked im-
munosorbent assay (ELISA), native and recombinant antigen based
enzyme-linked immuno electro transfer blot (EITB) techniques are
available but not commercialized for routine use (Allan et al., 2003;
Deckers and Dorny, 2010). Real time polymerase chain reaction for
taeniosis diagnosis has also been developed (Carabin et al., 2017). T.
solium neurocysticercosis is routinely diagnosed by imaging (computed
tomography (CT), magnetic resonance imaging (MRI)) supported by
various serological methods principally antibody and antigen ELISA
(B158/B60, HP10) and EITB. The lentil lectin purified glycoprotein (LL
GP)-EITB is the test of choice (Deckers and Dorny, 2010; Del Brutto
et al., 2017).
Diagnosis of cystic and alveolar echinococcosis is principally by
clinical signs, imaging (ultrasonography (US)), MRI, magnetic re-
sonance cholangiopancreatography (MRCP)), supported by serological
methods such as, indirect hemagglutination, ELISA, latex agglutination
and point of care tests (Brunetti and White, 2012; Tamarozzi et al.,
2016).
Diagnosis of FBT is mainly by imaging (US, CT), parasitological
methods, immunodiagnostic and molecular techniques. The main
parasitological methods are detection of eggs in fecal samples using the
Kato Katz method, formalin ether concentration method, dilution egg
count and sedimentation techniques (Fürst et al., 2012). Fecal egg de-
tection and worm recovery following treatment are the present “gold
standard” for Clonorchis and Opisthorchis diagnosis (Johansen et al.,
2015). Immunodiagnostic tests such as, intradermal test, indirect he-
magglutination, indirect fluorescent antibody test, indirect ELISA are
available. Molecular-based tests have also been developed though they
are not routinely used (Fürst et al., 2012).
In most resource limited settings, simple diagnostic tests such as,
microscopy can be used. However, besides the inherently low sensi-
tivity and specificity, their throughput is limited for large epidemiolo-
gical studies. The existing immune- and molecular diagnostic tests re-
quire expensive equipment, infrastructure and highly skilled personnel,
all of which are very scarce in resource limited settings. The lack of
robust, sensitive and specific diagnostic tests which are also cheap, easy
to use and suitable for endemic areas is a recognized challenge (Le and
Hsieh, 2017; Wu et al., 2017), and a call for simple and easy to use
rapid diagnostic tests has been made (Schwarz et al., 2017). For tae-
niosis and cysticercosis, target product profiles have been developed,
including rapid point of care (POC) tests as well as reference tests for
confirmation (Donadeu et al., 2017; WHO, 2015c).
The objective of this study was to give an update of progress on the
development of rapid diagnostic tests (RDT) for taeniosis/cysticercosis,
echinococcosis and FBT in humans, by giving an overview of the cur-
rently available rapid tests, and summarizing their characteristics.
Moreover, the operational suitability of commercialized POC tests for
FNZH in endemic areas was assessed using a standardized score card
(Lehe et al., 2012).
2. Methods
For the purpose of this study, RDT is defined as qualitative or semi-
quantitative in vitro diagnostic medical device, used singly or in a small
series, which involves non-automated procedures and has been de-
signed to give a fast result (2009/886/EC). A POC test is defined as by
the ASSURED criteria: (1) Affordable by those at risk of infection, (2)
Sensitive (few false-negatives), (3) Specific (few false-positives), (4)
User-friendly (simple to perform and requiring minimal training), (5)
Rapid (< 30min), (6) Robust (does not require refrigerated storage),
and (7) Equipment-free delivered to those who need it (Peeling and
Mabey, 2010; Wu and Zaman, 2012). This POC definition has only been
applied to commercialized rapid tests for scorecard evaluation. For
other tests, a definition based on target settings of deployment has been
used.
This systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta Analyses (PRISMA)
guidelines in April 2018 (Moher et al., 2009). Information was collected
on the development and evaluation of RDTs for foodborne neglected
zoonotic helminths since 2010.
2.1. Eligibility criteria
2.1.1. Inclusion criteria
The eligibility of studies to be included followed the PICOS (popu-
lation, interventions, comparison, outcomes and study design) criteria:
(1) Population - Any rapid tests for diagnosing T. solium infections,
Echinococcosis and FBTs in human populations that can be used in four
target settings; home, community, clinic and peripheral laboratory (Pai
et al., 2012), (2) Interventions (Index tests) – Any technology for ra-
pidly diagnosing any of the three classes of FNZH using acceptable
reference tests meeting the STARD (Standards for reporting diagnostic
accuracy studies) quality assessment criteria, (3) Comparator – Re-
ference tests, gold standard, in their absence, results of several tests for
the same condition, (4) Outcome – Studies that have reported diag-
nostic accuracy, precision, diagnostic sensitivity and specificity, ana-
lytical sensitivity and specificity, (5) Study design - Study designs in
single gate or two gate formats as well as those in early development
but report parameters under outcomes above, and (6) Others - Studies
in English from 1st January 2010 to date.
2.1.2. Exclusion criteria
Publications covering the following topics were excluded; (1)
Publications regarding pathogens other than the FNZH described
above, (2) Diagnostic tests that are not rapid for the diagnosis of the
FNZH, (3) Non-human rapid tests for FNZH, (4) Editorials or review
articles without original data.
2.2. Information sources
Information was obtained from online databases; PubMed, Web of
Science and Embase.
2.3. Search
The search was conducted in all three databases on the 6th of April
2018. One search phrase was used in all three databases and read as
follows;
(Point of care test OR POC OR rapid test OR rapid assay OR quick
test OR lateral flow OR strip test) AND (taeni* OR cysticerc* OR
Neurocysticerc OR teni OR echinococc* OR Cystic hydatidosis OR hy-
datid OR Alveolar echinococcosis OR Foodborne trematodes OR FBT
OR Clonorchiasis OR Opisthorchiasis OR fascioliasis OR paragonimiasis
OR Fasciola hepatica OR Fasciola gigantic OR liver fluke OR oriental
liver fluke OR human fascioliasis)
Further hand searching and follow up of references was also done.
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2.4. Study selection
Studies were selected according to the PRISMA guidelines. Firstly,
duplicates were removed from the total publications searched for. The
remaining publications were screened on title and abstract and those
that did not meet the inclusion criteria were excluded. Publications
were then read in full and those that met the inclusion criteria were
included for data extraction.
2.5. Data collection process
Data was initially qualitatively obtained on all RDTs for the in-
cluded FNZH and listed according to the parasites they detected. The
performance characteristics of these tests were summarized. Then
commercialized POC tests were selected and subjected to evaluation of
operational characteristics using the standardized score card (Lehe
et al., 2012). Data was extracted by one reviewer (CM) and verified by
another (CT). Where there was disagreement, other reviewers were
consulted.
2.6. Data items
The following data was extracted: index test, reference tests, diag-
nostic sensitivity (se) and specificity (sp), analytical sensitivity and
specificity, cross reactions and when reported positive and negative
predictive values (PPV/NPV), study design, population description,
sample size, number of positive samples, number of negative samples,
test indication, intended use, target population and setting, location of
use, test format, portability, target analyte, sample type, steps to results,
nature of results, result record and author as well as publication year
(Fig. 1).
2.7. Risk of bias and quality of included studies
The risk of bias in individual included studies was assessed using the
guidelines of the Agency for Healthcare Research and Quality methods
guide for comparative effectiveness reviews (AHRQ) (Viswanathan
et al., 2012) (Fig. 2). The quality of included studies was assessed ac-
cording to the STARD guidelines (Cohen et al., 2016) (Fig. 3).
3. Results
3.1. Study selection
The search resulted in 480 titles and abstracts. After removal of
duplicates, 288 titles were retained. Of these 215 titles were excluded
for various reasons; 107 titles were not about the three groups of ne-
glected zoonotic helminths, while the other 107 papers covered subjects
other than diagnostic development/evaluation; one paper was in
French. Seventy three (73) publications were selected for full reading.
Fifty-one (51) publications were excluded due to other reasons: 46
publications covered NZH but not diagnostic evaluation while two were
in Chinese and two in Arabic. One publication could not be accessed
online. Finally, data was extracted from 22 publications.
3.2. Study characteristics
3.2.1. Risk of bias within studies
Assessment of risk of bias in individual included studies showed
that, most studies were biased on selection of subjects. There was no
Fig. 1. PRISMA Flow Diagram.
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Fig. 2. Risk of bias in included studies.
Fig. 3. Quality of studies included in the study based on the STARD checklist.
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randomization in selection of subjects or concealment of cases. Most
were case control studies while others, especially nucleic acid detecting
tests, were mainly laboratory based using DNA serial dilutions. One had
a component of field evaluation as a minor part. Less than 10% of the
studies reported blinding of laboratory analysts, or blinding of the in-
terpreters of reference results (Fig. 2).
3.2.2. Assessment of quality of included studies
The quality of included studies was acceptable according to the
STARD guidelines (Cohen et al., 2016). All studies were easily identi-
fiable as diagnostic accuracy studies, stated the research questions or
aims, and described the population, participant recruitment and sam-
pling, reference standard, rationale, specimen acquisition and discusses
clinical applicability of the findings. There were notable omissions in
some studies; the majority of studies did not describe mechanisms of
blinding and training in specimen processing, did not show how in-
determinate results were handled and did not report diagnostic accu-
racy results with statistical uncertainty (Fig. 3).
3.3. Synthesis of results
3.3.1. Rapid diagnosis of Taenia solium infections in humans
Data about rapid diagnosis of T. solium infections in humans was
retrieved from five studies, including diagnostic tests for taeniosis (1),
cysticercosis (5) and neurocysticercosis (2), summarized in Table 1.
Additional test characteristics have been summarized in Supplementary
Table 1. In total, eight RDTs have been developed.
3.3.1.1. Antibody detecting tests. Several tests targeting antibodies
against native and recombinant antigens have been developed. The
rES33- Magnetic immune-chromatographic (MICT) test detects
antibodies against adult T. solium excretory secretory proteins (TSES)
(Table 1) in serum using a recombinant protein in a magnetic labelled
detection system to improve sensitivity and to quantify the results of
the test. (Handali et al., 2010a). The diagnostic performance of rES33 in
this test format compares well with T. solium native excretory secretory
antigens (se 95% and sp 100%) (Wilkins et al., 1999) and the rES33
antigen (se 99.4, sp 93.9%) in an EITB format (Handali et al., 2010b).
The rES33 antigen has been found to cross react with serum of A.
lumbricoides, E. granulosus s.l., P. falciparum, S. mansoni and Trichinella
species patients (Handali et al., 2010b, 2010a), hence the lower
specificity. This test meets most of the target product profiles in the
minimum criteria of a POC test proposed by the WHO for diagnosing
taeniosis save for the fact that, it targets antibodies and not antigens as
suggested (Donadeu et al., 2017). The limitation of this test is that it
still uses a liquid conjugate and therefore requires a cold chain and a
reader. The bench top magnetic reader also makes it less portable to use
as a POC test in endemic areas (Handali et al., 2010a). Despite this, it
can be used at clinic level.
Several tests have been developed targeting antibodies against the
previously described recombinant T24H (rT24H) glycoprotein (Hancock
et al., 2006) in serum for cysticercosis diagnosis. The rT24H-MICT test
uses the same technology as the rES33-MICT; therefore, the advantages
and the disadvantages are similar. The Up-converting phosphor reporter
rT24H lateral flow assay (UCP-rT24H LFA) uses Up-converting Phosphor
(UCP) particles as a detection method (Ouellette et al., 2009). The results
are read using a multi strip reader after chromatography and when the
strips are dry. In this format, this test has been reported to detect low
amounts of antibodies (Corstjens et al., 2014). The ease of use is reduced
by the requirements of sample dilution, washing, conjugate application
and strip analysis. This limits its use to begin at the level of the clinic. The
rT24H antigen has been used in other test formats with reported sensi-
tivity and specificity as follows; Multi antigen print immune assay
(MAPIA), 97% and 99%, and EITB 94% and 99%, respectively. A cross
reaction with Schistosoma mansoni has been previously reported in the
MAPIA test format (Rodriguez et al., 2012).Ta
bl
e1
(co
nti
nu
ed
)
Di
sea
se
Ta
en
ios
is
Cy
sti
ce
rco
sis
Cy
sti
ce
rco
sis
Cy
sti
ce
rco
sis
Cy
sti
ce
rco
sis
Cy
sti
ce
rco
sis
(N
eu
ro
)c
ys
tic
erc
os
is
Ne
ur
oc
ys
tic
erc
os
is
Sa
mp
le
typ
ea
nd
qu
an
tit
y
Se
ru
m,
5μ
L
Se
ru
m,
5μ
L
Se
ru
m,
5μ
L
Se
ru
m,
5μ
L
Se
ru
m,
5μ
L
Se
ru
m,
40
μL
of
dil
ut
ed
sa
mp
le
Dr
op
of
CS
F/
ser
um
CS
F
Ti
me
to
res
ult
s
(M
inu
tes
)
25
15
60
60
60
30
2
10
Re
fer
en
ce
(H
an
da
li
et
al.
,2
01
0a
)
(H
an
da
li
et
al.
,2
01
0a
)
(L
ee
et
al.
,2
01
1)
(L
ee
et
al.
,2
01
1)
(L
ee
et
al.
,2
01
1)
(C
or
stj
en
se
ta
l.,
20
14
)
(B
isw
as
an
dP
ari
ja,
20
11
)
(F
leu
ry
et
al.
,2
01
6)
Ab
br
ev
iat
ion
s:
MI
CT
-m
ag
ne
tic
Im
mu
no
ch
ro
ma
tog
rap
hy
tes
t,
UC
P-
up
co
nv
ert
ing
ph
os
ph
or
rep
or
ter
PC
R-
Po
lym
era
se
ch
ain
rea
cti
on
,C
T-
Co
mp
ut
ed
tom
og
rap
hy
,M
RI
-M
ag
ne
tic
res
on
an
ce
im
ag
ing
,L
LG
PE
IT
B-
Le
nt
il-
lec
tin
pu
rifi
ed
gly
co
pr
ote
in
en
zy
me
-li
nk
ed
im
mu
no
-el
ec
tro
-tr
an
sfe
rb
lot
,C
SF
-C
ere
br
os
pin
al
flu
id,
CD
C-
Ce
nt
re
for
dis
ea
se
pr
ev
en
tio
n
an
d
co
nt
ro
lo
fA
tla
nt
a,
PP
V-
Po
sit
ive
pr
ed
ict
ive
va
lue
,N
PV
-N
eg
ati
ve
pr
ed
ict
ive
va
lue
,E
LIS
A-
En
zy
me
-li
nk
ed
im
mu
no
-so
rb
en
ta
ssa
y,
NC
C-
Ne
ur
oc
ys
tic
erc
os
is.
C. Mubanga, et al. Acta Tropica 194 (2019) 135–147
140
Ta
bl
e2
Su
mm
ary
ch
ara
cte
ris
tic
so
fr
ap
id
tes
ts
for
Ec
hin
oc
oc
cu
sg
ran
ulo
sus
s.l
.a
nd
E.
mu
ltil
oc
ula
ris
inf
ec
tio
ns
in
hu
ma
ns
.
Di
sea
se
Al
ve
ola
r/C
ys
tic
ec
hin
oc
oc
co
sis
Al
ve
ola
r
ec
hin
oc
oc
co
sis
(A
E)
Al
ve
ola
r/
Cy
sti
c
ec
hin
oc
oc
co
sis
Cy
sti
ce
ch
ino
co
cc
os
is
(C
E)
Cy
sti
ce
ch
ino
co
cc
os
is
(C
E)
Cy
sti
ce
ch
ino
co
cc
os
is
(C
E)
Cy
sti
c
ec
hin
oc
oc
co
sis
(C
E)
Cy
sti
c
ec
hin
oc
oc
co
sis
(C
E)
Ind
ex
Te
st
Do
ti
m
m
un
e-fi
ltr
at
io
n
go
ld
(D
IG
FA
)
rE
M
18
-IC
T
(A
DA
M
U
AE
)
HC
F-r
EM
18
-IC
T(
Im
m
un
o-
ch
ro
m
at
og
ra
ph
y
te
st)
Ag
B-
Di
p
sti
ck
rA
gB
8/
1-
IC
T
(A
DA
M
U
CE
)
Ag
B-
Ag
5_
IC
T
(V
IR
ap
id
hy
da
tid
os
is)
NA
DH
1-
LA
M
P
rA
gB
-IC
T
(h
yd
ra
pi
d)
Re
fer
en
ce
tes
t
Im
ag
ing
(U
ltr
as
ou
nd
,X
-ra
y,
CT
,
MR
I)
EL
ISA
,
Im
mu
no
blo
t,
Im
ag
ing
(M
RI
)
Cl
ini
ca
l,
im
ag
ing
,E
LIS
A
Im
ag
ing
(U
ltr
as
ou
nd
,
X-
ray
,C
T)
,p
ath
olo
gy
,
ser
olo
gy
Su
rg
ica
l,
ser
olo
gy
Ind
ire
ct
Ha
em
ag
lut
ina
tio
n,
EL
ISA
Su
rg
ery
Ul
tra
so
un
d
Di
ag
no
sti
cs
e%
Ho
sp
ita
lC
E:
80
.7,
AE
:9
2.9
94
CE
91
IgG
49
5
78
94
.7
–
64
Co
mm
un
ity
:C
E
94
.6,
AE
97
.1
AE
98
IgG
10
0
Di
ag
no
sti
cs
p%
Ho
sp
ita
lC
E:
93
.4
(A
gB
),
AE
:
90
.3
(E
M2
)
95
.4
CE
96
.9
IgG
41
00
89
.8
99
.5
–
86
–1
00
AE
99
.3
IgG
87
.5
An
aly
tic
al
se
–
–
–
–
Sin
gle
cy
sts
78
.8%
–
10
fg
–
Mu
lti
ple
cy
sts
76
.5%
An
aly
tic
al
sp
(O
th
er
dis
ea
ses
/p
ara
sit
es
be
ing
tes
ted
to
ev
alu
ate
sp
ec
ifi
cit
y)
Sim
ple
cy
sti
cd
ise
ase
,c
arc
ino
ma
,
tub
erc
ulo
sis
,s
pa
ce
oc
cu
py
ing
les
ion
s,
cir
rho
sis
,a
bsc
ess
,
cy
sti
cer
co
sis
,c
ho
lec
yst
itis
/
ga
llst
on
es,
oth
er
pa
tie
nts
E.
gra
nu
los
us
s.l
.
Se
ro
us
he
pa
tic
cy
sts
,
cy
sti
ce
rco
sis
,
sch
ist
os
om
ias
is,
tox
op
las
mo
sis
,
pa
rag
on
im
ias
is,
clo
no
rch
ias
is
Ma
lar
ia,
tox
oc
ari
as
is,
str
on
gy
loi
dio
sis
,
as
ca
ria
sis
,f
as
cio
lia
sis
,
tae
nio
sis
E.
mu
ltil
oc
ula
ris
,C
lon
orc
his
sin
en
sis
,T
.s
oli
um
,T
,s
ag
ina
ta,
Pa
rag
on
im
us
mi
ya
za
ki,
P.
we
ste
rm
an
i,S
ch
ist
oso
ma
he
ma
tob
ium
,S
pir
om
etr
a
eri
na
cei
–
Cy
sti
cer
cu
sb
ov
is,
Fa
sci
ola
gig
an
tic
a,
Sc
his
tos
om
ab
ov
is
–
Cr
os
sr
ea
cti
on
s
Ag
B
in
AE
,E
M2
in
CE
,
cy
sti
ce
rco
sis
No
ne
rep
or
ted
T.
sol
ium
cy
sti
ce
rco
sis
To
xo
ca
ria
sis
,
fas
cio
lia
sis
E.
mu
ltil
oc
ula
ris
–
No
ne
rep
or
ted
No
ne
rep
or
ted
Stu
dy
de
sig
n
Re
tro
sp
ec
tiv
e,
cro
ss
sec
tio
na
l
Re
tro
sp
ec
tiv
e
Re
tro
sp
ec
tiv
e
Cr
os
ss
ec
tio
na
l
Re
tro
sp
ec
tiv
e
Re
tro
sp
ec
tiv
e
Cr
os
ss
ec
tio
na
l
Re
tro
sp
ec
tiv
e
Po
pu
lat
ion
de
scr
ipt
ion
Ho
sp
ita
lr
efe
rra
ls
Ho
sp
ita
lr
efe
rra
ls
Ho
sp
ita
lr
efe
rra
ls
Ho
sp
ita
lr
efe
rra
ls
–
–
Ho
sp
ita
lr
efe
rra
ls
Ho
sp
ita
lr
efe
rra
ls
Sa
mp
le
siz
e
Re
tro
sp
ec
tiv
e1
60
2,
Pr
os
pe
cti
ve
31
91
94
32
2
53
20
6
27
6
10
0
87
Po
sit
ive
sa
mp
les
Re
tro
sp
ec
tiv
e:
85
7C
E,
42
AE
50
AE
19
5(
14
4C
E,
51
AE
)
21
50
77
10
0c
ys
ts
(5
0c
am
el,
40
ca
ttl
e,
10
hu
ma
n)
60
Pr
os
pe
cti
ve
16
0C
E,
10
8A
E
Ne
ga
tiv
es
am
ple
s
35
20
60
15
88
19
9
Nu
cle
ic
ac
id
fre
e
wa
ter
25
He
ter
olo
go
us
inf
ec
tio
ns
70
2
24
67
17
68
–
Pr
ese
nt
,n
um
be
rn
ot
me
nt
ion
ed
2
Te
st
for
ma
t
Mu
lti
ple
an
tig
en
im
mu
ne
-
fil
tra
tio
n
as
sa
y
Im
mu
no
-
ch
ro
ma
tog
rap
hy
Im
mu
no
-ch
ro
ma
tog
rap
hy
Im
mu
no
-
ch
ro
ma
tog
rap
hy
Im
mu
no
-ch
ro
ma
tog
rap
hy
Im
mu
ne
-
ch
ro
ma
tog
rap
hy
Lo
op
me
dia
ted
iso
th
erm
al
am
pli
fic
ati
on
tes
t
Im
mu
ne
-
ch
ro
ma
tog
rap
hy
Sa
mp
le
typ
ea
nd
qu
an
tit
y
Se
ru
m
20
μL
,h
ep
ari
niz
ed
blo
od
40
μL
Se
ru
m
10
μL
Se
ru
m
10
μL
,h
ep
ari
niz
ed
blo
od
20
μL
Se
ru
m
10
μL
Se
ru
m
10
μL
He
pa
rin
ize
db
loo
d,
ser
um
30
μL
Cy
st
DN
A
Se
ru
m
7μ
L
Ti
me
to
res
ult
s
(M
inu
tes
)
4
20
15
15
20
30
60
15
Re
fer
en
ce
(F
en
ge
ta
l.,
20
10
)
(Sa
ko
et
al.
,2
01
1,
20
09
)
(W
an
ge
ta
l.,
20
13
)
(K
ha
lilp
ou
re
ta
l.,
20
14
)
(Sa
nt
iva
ñe
ze
ta
l.,
20
15
)
(D
elg
ad
oe
ta
l.,
20
10
)
(A
hm
ed
et
al.
,2
01
6)
(V
ola
et
al.
,2
01
8)
Ab
br
ev
iat
ion
s:
HC
F-
Hy
da
tid
cy
st
flu
id,
IC
T-
Im
mu
no
ch
ro
ma
tog
rap
hy
tes
t,
NA
DH
-N
ico
tin
am
ide
ad
en
ine
din
uc
leo
tid
e,
LA
MP
-L
oo
pm
ed
iat
ed
iso
th
erm
al
am
pli
fic
ati
on
,A
E-
Al
ve
ola
re
ch
ino
co
cc
os
is,
CE
-C
ys
tic
ec
hin
o-
co
cc
os
is.
C. Mubanga, et al. Acta Tropica 194 (2019) 135–147
141
Quick ELISA™ has been adapted for sero-diagnosis of cysticercosis
based on the recombinant T24H and GP50 glycoproteins as well as
synthetic peptide sTs18var1 (Table 1). As such, it is suitable for ex-
posure surveillance of cysticercosis. Quick ELISA™ is a high throughput
quantitative assay which can be performed on the bench top but can
also be automated. It is suitable for field studies but requires a basic
laboratory due to; the number and type of samples, the buffers it uses
which require a cold chain and equipment such as, the absorbance
reader which requires electricity (Lee et al., 2011). The performance of
the rGP50 in other test formats, sensitivity and specificity; EITB 90%
and 100%, ELISA 95% and 94%, MAPIA 93% and 100%, is close to the
minimum requirement of 90% and 98%, respectively. False positives
reported for the rGP50 have not been linked to any particular parasitic
infections (Bueno et al., 2005; Rodriguez et al., 2012). The perfor-
mance, sensitivity and specificity, of the Ts18var1 in other test formats
reported are; EITB, 97% and 100%, ELISA 95% and 85%, another ELISA
90% and 90%, FAST ELISA 97% and 100%. There are no cross reactions
reported in other test formats on the rGP50 and sTs18var1 (Rodriguez
et al., 2012). The Quick ELISA seems to be a good test for use at the
periphery laboratory.
All the antibody detecting tests meet the minimum performance
requirements for cysticercosis diagnosis of sensitivity 90% and speci-
ficity 98%, proposed by the WHO in the target product profiles for
human cysticercosis, only tests based on sTs18var1 fall short (Donadeu
et al., 2017). The Quick ELISA rT24H showed the best performance
among the antibody detecting tests but for the detection of NCC, the Se
drops when the number of cysticerci is low.
3.3.1.2. Antigen detecting tests. The Rapid Slide/Latex Agglutination
test has been standardized and evaluated for the detection of T. solium
metacestode antigen in cerebral spinal fluid (CSF) and serum (Table 1).
It uses latex particles which have been sensitized by rabbit produced
hyper immune cysticercosis anti-serum. The agglutination is performed
on a glass slide where the latex suspension is added to a serum or CSF
sample. A positive test is seen by agglutination. Cross reactions with
tuberculous meningitis on both serum and CSF were reported. One
healthy control out of 25 serum samples tested positive (Biswas and
Parija, 2011). The test results were below the performance
requirements suggested for cysticercosis and NCC (Donadeu et al.,
2017). Nevertheless, the simplicity of the test format makes it easy for
single case diagnosis. Preparation of the latex suspension and
sensitization of latex particles are relatively easy, moreover they can
be stored at 4 °C for further use. This test can be deployed at clinic level
for serum, and hospital for CSF, the limitation being the needed
expertise to obtain CSF by lumbar puncture.
Another RDT reported for NCC is the HP10 LFA (Table 1) (Fleury
et al., 2016). The target analyte is the HP10 antigen in CSF, which is a
circulating surface as well as excretory secretory antigen in T. saginata,
T. hydatigena, T. solium and E. granulosus s.l. (Harrison and Parkhouse,
1989). The main purpose of this assay is post treatment monitoring in
patients with extra parenchymal NCC as well as supportive diagnosis
given that imaging is less sensitive for extra parenchymal NCC. The
HP10 antigen has been used in ELISA format for NCC diagnosis using
CSF and serum with sensitivity and specificity of 91.3% and 100%, and
84.8% and 98%, respectively (Fleury et al., 2007). The diagnostic
performance meets the suggested requirements for cysticercosis diag-
nosis. Further evaluation is needed using patients with multiple parasite
infections. The largest limitation of this test is the sample type. Despite
the test being easy to perform, the lumbar sampling procedure is in-
vasive and requires expertise. Therefore, the lowest level of deployment
of this test is the hospital.
3.3.2. Rapid diagnosis of Echinococcus granulosus s.l. and Echinococcus
multilocularis infections in humans
Data was extracted from eight publications about rapid diagnosis of
Echinococcus spp. infections due to E. granulosus s.l. which causes cystic
echinococcosis (CE) and E. multilocularis, which causes alveolar echi-
nococcosis (AE). The data has been combined for both diseases and
summarized in Table 2. Additional test characteristics have been sum-
marized in Supplementary Table 2.
3.3.2.1. Antibody detecting tests. Several rapid tests targeting antibodies
to native and recombinant antigens for E. granulosus s.l. and E.
multilocularis have been developed (Table 2). There are tests specific
for CE or AE, and combined tests for CE and AE. A number of tests for
CE diagnosis based on antigen B antibodies have been developed. The
Antigen B lateral flow dipstick (AgB-LF Dipstick) was evaluated for
rapid diagnosis of CE. The test format requires multiple dipping steps of
the stick in diluted serum, conjugate and wash buffer, limiting its use to
clinic level. The test cross reacted with fascioliasis and toxocariasis
patients sera (Khalilpour et al., 2014). The rAgB8/1-ICT (ADAMU-CE,
ICST corporation, Japan) is a commercialized immune-
chromatography lateral flow test based on recombinant antigen B
(Santivañez et al., 2015). Its test sensitivity was reported better on
patients with liver cysts compared to patients with lung cysts. A study
which compared the performance of three commercial tests (DIGFA
(Unibiotest, China), ADAMU-CE (ICST corporation, Japan), VIRapid
(Vircell, Spain)) for CE diagnosis reported the sensitivity of rAgB8/1-
ICT to be 57% (Tamarozzi et al., 2016), which is lower than previously
reported (Table 2). In this comparison study, VIRapid was the best
performing followed by DIGFA, then rAgB8/1-ICT in the diagnosis of
CE (Tamarozzi et al., 2016). Like the other two tests, the performance
varied with cyst stage and was good in viable cyst stages CE2-CE3
though poor in CE1 and non-viable cyst stages C4 and C5. The
specificity was lower (89.8%) in studies including AE patients and
higher (100%) without AE patients. However, it is still a simple test
useable at community level. The Antigen B and Antigen 5 Immuno-
chromatography test (AgB-Ag5-ICT) (the commercial name is VIRapid
hydatidosis) is a lateral flow test based on the most immunogenic
purified antigens of E. granulosus s.l., AgB and Ag5, (Sarkari and Rezaei,
2015) developed in 2010 (Delgado et al., 2010). It detects antibodies
against these two antigens. It has been evaluated as a screening and
diagnostic test (Tamer et al., 2015). The average diagnostic sensitivity
reported varies; 94.7% (Delgado et al., 2010), 96.8% (Tamer et al.,
2015), 74.1% (Tamarozzi et al., 2016), 82.3% and 80% in a large scale
evaluation using both retrospective and prospective study designs
(Baraquin et al., 2017), and most recently 69% (Vola et al., 2018).
Sensitivity has been shown to vary with cyst stage and status. The test
sensitivity is best in viable stages CE2-CE3b and poorer for CE1 and the
inactive stages of CE4 and CE5. Similarly, its specificity has been
reported to range from 80.9% to 100%. The test is deployable at
community level. Another rAgB-ICT based rapid test has been
developed to detect antibodies against antigen B of E. granulosus s.l.,
based on a similar dipstick format as the AgB-LF dipstick (Vola et al.,
2018), also deployable at clinic level.
Some rapid tests have been developed for differential/concurrent
diagnosis of CE and AE, rendering them specifically relevant for use in
co-endemic areas (Table 2). The Echinococcosis Dot Immuno-Gold
Filtration Assay (DIGFA, Unibiotest, China) is a commercialized rapid
test based on the specific E. multilocularis EM2 antigen and three E.
granulosus s.l. antigens: AgB, EgCF (partially purified cyst fluid) and EgP
(protoscolex). The DIGFA was tested on hospital samples as well as on
samples from community-based surveys (Feng et al., 2010). It is a POC
deployable at community level. Another differential immune-chroma-
tography test (ICT) design, the HCF-rEM18-ICT, uses two antigens,
hydatid cyst fluid (HCF) for E. granulosus s.l. and the recombinant EM18
for E. multilocularis (Wang et al., 2013). Important to note is that the
antibodies against the rEM18 antigen cross reacts with HCF antigens,
though at a very low level (Knapp et al., 2014; Wang et al., 2013). The
simplicity of this test makes it suitable for community deployment.
Some developed tests are specific to AE diagnosis (Table 2). The
rEM18-ICT (Immunochromatography, ADAMU-AE) is a
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commercialized test for diagnosis of E. multilocularis based on anti-
bodies against an 18 kDa antigen (Em18), one of the products of cy-
steine peptidase on ezrin-radin-moesin like protein. The rEM18-ICT was
evaluated for rapid clinical diagnosis (Sako et al., 2009), post treatment
follow up (Sako et al., 2011) and reliability as a first screening test
(Knapp et al., 2014). In the 2014 study, the reported sensitivity was
90% and specificity of 92.7%. The evaluation studies have reported
cross reactions with CE, human liver cysts, toxocariasis and hepatic
carcinoma (Knapp et al., 2014; Sako et al., 2009). This test is suitable
for community deployment.
Antibodies against CE and AE antigens have been reported to cross
react with each other and with various parasitic and non-parasitic
conditions. Feng (Feng et al., 2010) demonstrated cross reactions be-
tween CE and AE of about 35% and that AgB, EgCF, EgP and EM2 all
cross reacted with T. solium cysticercosis. Other studies have reported
that EgCF, AgB and Ag5 cross reacts with Toxocara, Trichomonas, ma-
lignancies, serous cysts and Leishmania (Sarkari and Rezaei, 2015).
Antibodies against the EM2 antigen also cross react with the HCF an-
tigens though at a low level (Knapp et al., 2014; Wang et al., 2013).
3.3.2.2. Nucleic acid detecting tests. The loop mediated isothermal
amplification (LAMP) test for CE, NADH-1 LAMP-CE, is based on the
mitochondrial NADH dehydrogenase subunit 1 gene (Ahmed et al.,
2016). It was designed for postsurgical confirmation of CE using DNA
extracted with a commercial kit. The results are visualized by color
change of the included dye. The test showed no cross amplification with
DNA from T. saginata cysticerci, Schistosoma bovis and Fasciola gigantica
(Ahmed et al., 2016). E. multilocularis DNA was not included in the
controls. The test performance is comparable to the ultrasound
threshold for abdominal CE. However, its usefulness is limited due to
the fact that it needs cyst DNA as sample. The DNA extraction step
confines its use to laboratories and near hospitals where such surgical
procedures to remove cysts can be performed.
The diagnostic performance of tests for echinococcosis are normally
compared with ultrasound, which is the “best generally available” di-
agnostic test. In community studies, it has been reported with sensi-
tivity range of 88–98% for abdominal CE and AE. The specificity ranges
between 93–100% for both conditions (Macpherson and Milner, 2003).
Only three rapid tests have reported performance comparable to this
threshold; HCF-rEM18 ICT, AgB lateral flow dipstick and the LAMP CE.
3.3.3. Rapid diagnosis of foodborne trematode infections
Data was extracted from nine publications: three publications for
Fasciola spp. (3 tests), three for Opisthorchis spp. (3 tests), two for
Clonorchis spp. (2 tests), and one for Paragonimus spp. (1 test). Data is
presented according to the parasite species in Table 3. Additional test
characteristics have been summarized and presented in Supplementary
Table 3.
3.3.3.1. Human fascioliasis. Three rapid diagnostic tests for human
fascioliasis have been developed, two antibody and one nucleic acid
detecting test (Table 3). The recombinant pro-Cathepsin L1-serofluke
(rpCL1-serofluke) test uses recombinant pro-cathepsin L1 and targets
antibodies against Cathepsin, a cystein protease, for sero-diagnosis of
fascioliasis caused by both Fasciola gigantica and F. hepatica in low
resource settings (Martínez-Sernández et al., 2011). There were no
cross reactions reported. Similarly, other studies have also not found
cross reactions on cathepsin-based ELISA (Gonzales Santana et al.,
2013), and reported good performance (Sarkari and Khabisi, 2017). The
dipstick format which uses diluted serum and blood as samples does not
allow easy distribution and operation by non-technical community
health workers. The Excretory-Secretory (ES)-dip stick is similar in
format to the rpCL1-serofluke but detects antibodies against Fasciola ES
antigens which cross react with Schistosomiasis (Ali, 2012). The
Intergenic spacer (IGS)-LAMP was designed to differentially amplify
extracted DNA for F. hepatica and F. gigantica from fecal samples. It did
not amplify DNA from other parasite species included in the evaluation
(Ai et al., 2010). The DNA extraction step, and the use of a water bath
limits the infrastructure level of use. All tests for human fascioliasis are
suitable for use at peripheral laboratory level.
3.3.3.2. Human opisthorchiasis. Three nucleic acid detecting tests were
found for Opisthorchis viverrini infections (Table 3). All the tests use
extracted parasite DNA as a sample. TheMito (Mitochondria)-LAMP is
based on mitochondrial nicotinamide hydrogenase gene (nad1) (Le et al.,
2012). The internal transcribed spacers 1(ITS1) - (ITS1-LAMP) was
developed for diagnosis of O. viverrini (Arimatsu et al., 2012) but it
amplified DNA for Opisthorchis felineus and 5 other stool samples which
were considered negative on microscopy (Arimatsu et al., 2015, 2012).
The OVMS (Opisthorchis viverrini microsatellite) - LAMP is very
specific and also a thousand times more sensitive than the ITS1-LAMP.
Its analytical specificity was also better, other parasite DNA tested were
not amplified (Arimatsu et al., 2015). The complexity of LAMP,
especially the DNA extraction step limits its use to peripheral
laboratories.
3.3.3.3. Human clonorchiasis. The Cytochrome C oxidase subunit 1
(cox1)-LAMP DNA test for Clonorchis sinensis is based on the cox1 gene
(Rahman et al., 2017). This test can be used in peripheral laboratories
based in endemic locations. The Gold Immunochromatography Assay
(GICA) is an antibody detecting rapid test based on a yeast produced
recombinant antigen that was not specified. The test sensitivity is
lowest in light infections although it generally has good performance in
light, moderate and heavy infections (Li et al., 2018). This test is simple
to perform and can be used at community level.
3.3.3.4. Human paragonimiasis. The excretory-secretory lateral flow
assay (ES-LFA) of Paragonimiasis skrjabini detects antibodies against
excretory-secretory antigens. The reported sensitivity and specificity is
94.4% and 94.1%, respectively. Cross reactions with schistosomiasis
and clonorchiasis positive samples were observed (Wang et al., 2014).
The test is sufficiently simple but has a stage of serum dilution and
cannot easily be used in a community setting but rather at clinic level in
endemic areas.
3.3.4. Assessment of the diagnostic technology for commercialized point of
care tests used in diagnosis of foodborne neglected zoonotic helminths using
a standardized scorecard
Evaluation of diagnostic tests has largely been based on diagnostic
performance, often reported as sensitivity and specificity, and other
diagnostic accuracy measures such as, predictive values, likelihood
ratios, odds ratios and area under the curve (Cohen et al., 2016; Eusebi,
2013). In some studies, operational characteristics of diagnostic tests
are being included (Bocoum et al., 2015). Diagnostic tests for use in
resource limited settings are additionally evaluated for operational
performance in the absence of robust laboratory infrastructure. These
tests which can be applied at the patient side in non-laboratory settings
have been defined differently (Drain et al., 2014). A criteria, called the
ASSURED was developed by WHO and applied to Human Im-
munodeficiency Virus (HIV) (Affordable (less than $500/machine, less
$10/test), Sensitive (Acceptable analytical sensitivity: 500 HIV RNA
copies/ml, 350 CD4+T cells/μl), Specific, User-friendly (1–2 days
training), Rapid (less than 30min for diagnosis, less than 1.5 h for HIV
load monitoring) and Robust, Equipment free or minimal and Deliver-
able to remote areas) (Wu and Zaman, 2012). This eight parameter
criteria, which was specific to HIV tests has been expanded to include
other essential parameters such as, features of consumables, quality and
cost, enabling universal assessment of diagnostic tests in general and
point of care tests specifically regardless of the disease they diagnose
(Lehe et al., 2012). These expanded criteria use a score card with
predefined weightings on each parameter. The results of the scorecard,
given out of a 100 maximum scores can pass for percentage scores.
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Where it has been used, test scores ranged between 71–100% (Lehe
et al., 2012). The purpose of the score card is to rank and identify
strengths and weaknesses of rapid tests based on their operational
characteristics. In the reviewed manuscripts, the scorecard was applied
to assess the operational suitability of three commercialized point of
care tests for diagnosis of cystic echinococcosis. These tests are VIRapid
(Vircell, Spain) (Delgado et al., 2010), DIGFA (UniBiotest, China)(Feng
et al., 2010) and ADAMU-CE (ICST Corporation, Japan) (Santivañez
et al., 2015) already discussed above. In this assessment, the last ca-
tegory of “distribution and service” which is country-specific was
omitted so that the results can be generalized to any area, hence the
total percentage weighting is 91% instead of 100% VIRapid performed
best among the three diagnostic tests in this assessment (Table 4).
4. Discussion
In total, 25 rapid tests for the diagnosis of FNZH have been devel-
oped or further evaluated since 2010. Of the 25, there were eight RDT
for T. solium infections, eight for echinococcosis and nine for FBT in-
fections.
The majority of study designs (Fig. 2) were case-control studies in
which subjects were not randomly selected. As such, the reported di-
agnostic performance was biased upwards (Whiting et al., 2013).
However, when tests were subjected to evaluation in endemic popula-
tions, diagnostic performance was reduced due to spectrum of disease
(Abdul et al., 2015). Given the varying disease prevalence that results
from major interventions, it is important that these diagnostic tests are
extensively evaluated to obtain full information on test performance in
different epidemiological situations. Many RDTs that have been de-
veloped for FNZH have not undergone field performance evaluation.
For LAMP tests, most were only evaluated on serial dilutions of DNA to
obtain the analytical performance. To facilitate field performance
evaluation, some NTDs such as Schistosoma spp., blinding trachoma,
soil transmitted helminths and T. solium infections have diagnostic
target product profiles produced to guide research and development of
diagnostics (Donadeu et al., 2017; PATH, 2015). We have not come
across target product profiles for diagnostic tests for Echinococcus and
foodborne trematodes infections. Furthermore, beyond diagnostic ac-
curacy evaluation, there is need to evaluate the clinic impact of rapid
diagnostic tests on patient centered outcomes (Drain et al., 2014). The
study quality as shown in Fig. 3 was generally similar in pattern. Few
studies reported blinding and training of people involved in the diag-
nosis. Only 77% of the studies had a cross tabulation of results, nearly
all nucleic acid detecting tests results were not cross-tabulated. The use
of statistical uncertainties was limited to only 32% of the studies. The
STARD provide guidelines on reporting of diagnostic studies (Cohen
et al., 2016). This review should therefore be interpreted in the light of
information from Figs. 2 and 3.
Operational characteristics of three commercialized tests for E.
granulosus s.l., VIRapid, DIGFA and ADAMU CE have been evaluated
using a standardized scorecard (Lehe et al., 2012). Based on our results,
the VIRapid is the best suited operationally for use in low resource
settings with a score of 68.77%. Coupled with the score on diagnostic
evaluation (Baraquin et al., 2017), VIRapid would be the test of choice
for CE in low resource settings. The evaluation on ADAMU CE was
limited as the manufacturers did not provide further information re-
quired beyond what was on the product leaflet. Therefore, the assess-
ment scores on heat stability of reagents and controls, shelf life and
reagent, consumable and control costs were used at minimum scores. It
is possible that, had the information been available, the overall scores
could alter the sequence, especially with the DIGFA, which is just a few
points above the ADAMU CE. The limitation with using the scorecard or
the ASSURED criteria on diagnostic test is that some components of
both criteria can only be determined in a marketed product. For ex-
ample, affordability in ASSURED (less than $10) or cost in the scorecard
is only known in commercialized products while in-development tests,
these can only be estimated. Thus, in this study, cost was not part of the
assessment for a test to meet the criteria. Furthermore, some thresholds
are very species specific. For example, analytical sensitivity which has
been described is specific to the human immunodeficiency virus (Wu
and Zaman, 2012). This may explain why the two criteria have been
used in assessment of commercial products only and not tests under
development (Kelly et al., 2017; Lehe et al., 2012; Marks and Mabey,
2017). However, these two criteria stand as the closest reference de-
scription of POC tests that are available.
5. Conclusions
The results show that there is development of RDTs for FNZH. Most
of the developed serological tests are based on the same antigens only
changing test formats. The developed tests, despite their limitations are
potentially capable of being used as tools in mapping and intervention
monitoring especially when integrated with conventional tests. Further
evaluation of most of these tests is needed to provide sufficient in-
formation on their applicability to endemic areas especially in low re-
source settings. There is also need to determine the value add of these
tests in health outcomes of individuals. Further research is needed on
the effect of test format on diagnostic performance.
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